Penentuan Model Prediktif Metastasis Tulang dan Prognosis Kanker Prostat Menggunakan Alkalin Fosfatase dan Skor Gleason
DOI:
https://doi.org/10.35790/msj.v6i1.48491Abstract
Abstract: To date, assessment of the prognostic ability based on the relationship between alkaline phosphatase (ALP) to the Gleason score has not been reported. This study aimed to compare ALP with Gleason score as a predictor of prostate cancer prognosis. This was a hospital-based cross sectional study conducted from January 1, 2019 to December 31, 2021. Prostate cancer patient information included demographics, disease history, clinical characteristics, laboratory and radiology tests, and histopathology results. The results showed that the majority had a poor degree of differentiation (Gleason score: 8-10), which was 85.5%. High serum prostate specific antigen (PSA) levels were associated with the scores. The results of ALP were normal in 59.4%, increased in 34.4%, and decreased in 6.3% of patients. The multivariate regression analysis showed that every 10 U/L increase in ALP in the blood of prostate cancer patients on average was associated with a worse prognosis characterized by an increase in Gleason score of about 0.06 points (95% CI 0.03-0.09; p=0.002). In conclusion, serum alkaline phosphatase can be a predictive factor of bone metastases in prostate cancer with a cut value of 102 IU/L. Each increase of 10 IU/L of serum ALP is associated with a worse prognosis in prostate cancer while the Gleason score cannot be a predictive indicator of bone metastases in prostate cancer.
Keywords: alkaline phosphatase; prostate specific antigen; Gleason score; prognostic predictor
Abstrak: Penilaian kemampuan prognostik kanker prostat berdasarkan hubungan alkalin fosfatase (ALP) dengan skor Gleason sampai saat ini belum pernah dilaporkan. Tujuan penelitian ini untuk membandingkan kadar ALP dengan skor Gleason sebagai prediktor prognosis kanker prostat. Penelitian ini menerapkan desain potong lintang berbasis rumah sakit dari 1 Januari 2019 hingga 31 Desember 2021. Informasi pasien kanker prostat mencakup demografik, riwayat penyakit, karakteristik klinik, hasil pemeriksaan laboratorium dan radiologi, serta data histopatologi. Hasil penelitian memperlihatkan proporsi terbesar memiliki tingkat diferensiasi buruk dengan skor Gleason: 8-10 sebesar 85,5%. Data tingginya kadar prostate specific antigen (PSA) serum berhubungan dengan skor Gleason. Pada penelitian ini ALP dengan hasil normal 59,4%, meningkat 34,4%, menurun 6,3%. Hasil analisis regresi multivariat menunjukkan setiap 10 U/L kenaikan ALP dalam darah pasien kanker prostat rata-rata berhubungan dengan prognosis lebih buruk ditandai oleh peningkatan skor Gleason sekitar 0,06 poin (95% CI 0,03-0,09; p=0,002). Simpulan penelitian ini ialah ALP dapat menjadi faktor prediksi metastase tulang pada kanker prostat dengan nilai potong 102 IU/L. Setiap peningkatan 10 IU/L ALP serum berhubungan dengan prognosis yang lebih buruk pada kanker prostat sedangkan skor Gleason tidak dapat menjadi indikator prediksi metastase tulang pada kanker prostat.
Kata kunci: alkaline fosfatase; prostate specific antigen; skor Gleason; prediktor prognosis
References
Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15(11):e484–92. Doi: 10.1016/S1470-2045(14)70211-6.
Akimoto S, Furuya Y, Akakura K, Shimazaki J, Ito H. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase. Int J Urol. 1997;4(6):572–5. Doi: 10.1111/ j.1442-2042.1997.tb00311.x.
Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol. 1996;155(4):1348–51. Available from: http://dx.doi.org/10.1016/s0022-5347(01)66263-3
Peng C, Juan C, Mao W, Jinghe Y, Renli T. Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients. Eur Rev Med Pharmacol Sci. 2022 ;26(11):3832-9. Doi: 10.26355/eurrev_202206_28950
Chen S, Wang L, Qian K, Jiang W, Deng H, Zhou Q, et al. Establishing a prediction model for prostate cancer bone metastasis. Int J Biol Sci. 2019;15(1):208–20. Doi: 10.7150/ijbs.27537
Chaoying L, Chao M, Xiangrui Y, Yingjian H, Gang Z, Yunhan R, Yu G. Risk factors of bone metastasis in patients with newly diagnosed prostate cancer. Eur Rev Med Pharmacol Sci. 2022;26(2):391–8. Doi: 10.26355/eurrev_202201_27863.
Mori K, Janisch F, Parizi MK, Mostafaei H, Lysenko I, Enikeev DV, et al. Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2020;25(2):247–57. Doi: 10.1007/s10147-019-01578-9.
Tsuzuki S, Kawano S, Fukuokaya W, Mori K, Nishikawa H, Tashiro K, et al. Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer. Jpn J Clin Oncol. 2021;51(11): 1665–71. Doi: 10.1093/jjco/hyab115.
Solang VR, Monoarfa A, Tjandra F. Profil penderita kanker prostat di RSUP Prof. Dr. R. D. Kandou Manado periode tahun 2013-2015. e-CliniC. 2016;4(2). Doi: https://doi.org/10.35790/ecl.v4i2.14371
Dany YA, Hendri AZ, Soerohardjo I. Prostate cancer profile in Dr. Sardjito General Yogyakarta. J Med Sci (Berkala Ilmu Kedokteran). 2021;53(3). Available from: https://doi.org/10.19106/ JMedSci005303202104
Mullins JK, Loeb S. Environmental exposures and prostate cancer. Urol Oncol. 2012;30(2):216–9. Doi: 10.1016/j.urolonc.2011.11.014.
Kaiser A, Haskins C, Siddiqui MM, Hussain A, D’Adamo C. The evolving role of diet in prostate cancer risk and progression. Curr Opin Oncol. 2019;31(3):222–9. Doi: 10.1097/CCO.0000000000000519.
Sanjaya IPG. Korelasi antara gleason score dan prostate specific antigen yang rendah dengan insiden metastasis tulang pada pasien kanker prostat: kapan untuk tidak melakukan bone scan [Tesis]. Jakarta: Universitas Indonesia; 2015. URI: https://lib.ui.ac.id/detail?id=20414167&lokasi=lokal
Bayu P, Hadibrata E, Triyandi R, Hanriko R. Hubungan kadar prostate specific antigen (PSA) dengan derajat histopatologi kanker prostat di RSUD Dr. H. Abdoel Moloek Provinsi Lampung periode 2019-2020. J Agromedicine Unila. 2021;8(1):1–9.
Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(5):479–505. Doi: 10.6004/jnccn.2019.0023.
Ozdemir S, Ersay AR, Koc Ozturk F, Ozdemir BS. Predictive value of standard serum markers for bone metastases in prostate cancer. Afr J Urol. 2021;27(1):1-6. Available from: https://doi.org/ 10.1186/ s12301-021-00170-w
Wei RJ, Li TY, Yang XC, Jia N, Yang XL, Song HB. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases. Genet Mol Res. 2016;15(2):15. Doi: 10.4238/gmr.15027707.
Ozu C, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M. Prediction of bone metastases by combination of tartrate‐resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol. 2008;15(5):419-22. Doi: 10.1111/j.1442-2042.2008.02029.x.
Shepherd KL, Cool P, Cribb G. Prognostic indicators of outcome for patients with skeletal metastases from carcinoma of the prostate. Bone Joint J. 2018;100(12):1647-54. Available from: https: //doi.org/ 10.1302/0301-620X.100B12.BJJ-2018-0697.R1
Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink HJ. Routine bone scans in patients with prostate cancer related to serum prostate‐specific antigen and alkaline phosphatase. BJU Int. 2001;88(3):226-30. Doi: 10.1046/j.1464-410x.2001.02275.x.
Amoako YA, Hammond EN, Assasie-Gyimah A, Laryea DO, Ankrah A, Amoah G. Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer. World J Nucl Med. 2019;18(02):143-8. Doi: 10.4103/wjnm.WJNM_38_18
Lai MHY, Luk WH, Chan JCS. Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population. Urol Oncol. 2011;29(3):275-9. Doi: 10.1016/ j.urolonc.2009.05.007.
Navisa CC, Sandhika W, Arwati H. Hubungan antara kadar prostate specific antigen serum dan skor Gleason pada adenokarsinoma prostat. Jurnal Kedokteran Brawijaya. 2019;30(3):181-4. Available from: https://doi.org/10.21776/ub.jkb.2019.030.03.3
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Marcella Merung, Christof Toreh, Ari Astram, Fredrik G. Langi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
